Fig. 3From: Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trialCost-effectiveness acceptability curves A when the charity assistance plan was not available; B when the charity assistance plan was availableBack to article page